197 related articles for article (PubMed ID: 18006840)
21. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis.
Conrotto P; Roesli C; Rybak J; Kischel P; Waltregny D; Neri D; Castronovo V
Int J Cancer; 2008 Dec; 123(12):2856-64. PubMed ID: 18798264
[TBL] [Abstract][Full Text] [Related]
22. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
23. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
Sahin U; Koslowski M; Dhaene K; Usener D; Brandenburg G; Seitz G; Huber C; Türeci O
Clin Cancer Res; 2008 Dec; 14(23):7624-34. PubMed ID: 19047087
[TBL] [Abstract][Full Text] [Related]
24. Extra domain A and type III connecting segment of fibronectin in assembly and cleavage.
Abe Y; Bui-Thanh NA; Ballantyne CM; Burns AR
Biochem Biophys Res Commun; 2005 Dec; 338(3):1640-7. PubMed ID: 16277979
[TBL] [Abstract][Full Text] [Related]
25. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.
Ronca R; Sozzani S; Presta M; Alessi P
Immunobiology; 2009; 214(9-10):800-10. PubMed ID: 19625102
[TBL] [Abstract][Full Text] [Related]
26. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E
Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147
[TBL] [Abstract][Full Text] [Related]
27. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
28. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
29. Recombinant antibodies for the selective targeting of tumor neovasculature.
Viti F; Giovannoni L; Neri D
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):204-13. PubMed ID: 11926127
[TBL] [Abstract][Full Text] [Related]
30. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
31. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
32. Fibronectin-targeted drug delivery in cancer.
Kumra H; Reinhardt DP
Adv Drug Deliv Rev; 2016 Feb; 97():101-10. PubMed ID: 26639577
[TBL] [Abstract][Full Text] [Related]
33. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer.
Sun B; Zhang S; Zhang D; Li Y; Zhao X; Luo Y; Guo Y
Clin Cancer Res; 2008 Nov; 14(21):7050-9. PubMed ID: 18981002
[TBL] [Abstract][Full Text] [Related]
34. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
35. Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients.
Warawdekar UM; Zingde SM; Iyer KS; Jagannath P; Mehta AR; Mehta NG
Clin Chim Acta; 2006 Oct; 372(1-2):83-93. PubMed ID: 16730689
[TBL] [Abstract][Full Text] [Related]
36. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment.
Bijian K; Mlynarek AM; Balys RL; Jie S; Xu Y; Hier MP; Black MJ; Di Falco MR; LaBoissiere S; Alaoui-Jamali MA
J Proteome Res; 2009 May; 8(5):2173-85. PubMed ID: 19284786
[TBL] [Abstract][Full Text] [Related]
37. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
38. Molecular correlates of site-specific metastasis.
Dai CY; Haqq CM; Puzas JE
Semin Radiat Oncol; 2006 Apr; 16(2):102-10. PubMed ID: 16564445
[TBL] [Abstract][Full Text] [Related]
39. Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry.
Zhang K; Wrzesinski K; Stephen JF; Larsen PM; Zhang X; Roepstorff P
Proteomics; 2008 Dec; 8(23-24):4932-45. PubMed ID: 19003861
[TBL] [Abstract][Full Text] [Related]
40. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma.
Liu YF; Xiao ZQ; Li MX; Li MY; Zhang PF; Li C; Li F; Chen YH; Yi H; Yao HX; Chen ZC
J Pathol; 2009 Jan; 217(1):54-64. PubMed ID: 18798225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
